The rosiglitazone controversy: The Indian perspective

Journal of Association of Physicians of India

Volumn 55, Issue JULY, 2007, Pages 477-480

  Mohan, V ^a   Joshi, Shashank R ^b  

^a MADRAS DIABETES RESEARCH FOUNDATION   (India)

^b LILAVATI HOSPITAL AND RESEARCH CENTRE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ROSIGLITAZONE;

CHEMICALLY INDUCED DISORDER; CORONARY ARTERY ATHEROSCLEROSIS; DRUG SCREENING; EDITORIAL; HUMAN; INDIA; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; STANDARD;

CORONARY ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION; HUMANS; HYPOGLYCEMIC AGENTS; INDIA; META-ANALYSIS; THIAZOLIDINEDIONES;

EID: 34347407190     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (21)

1. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287:360-72.
2. http://rezulin-lawsuit-lawyer.com/index.html. Accessed on June 19, 2007.
3. www.fda.gov/ohrms/dockets/AC/04/transcripts/2004-4062T1.pdf. Accessed on June 19, 2007.
4. Hollenberg NK. Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am J Med 2003;115 Suppl 8A:111S-115S.
5. Vidhya S, Mohan V. Rosiglitazone - Useful drug but has side effects. J Assoc Physicians India 2002;50: 615.
6. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368:1096-1105.
7. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.
8. Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, et al. A Diabetes Outcome Progression Trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002; 25:1737-43.
9. http://docnews.diabetesjournals.org/cgi/content/full/4/3/9. Accessed on June 19, 2007.
10. Joshi SR, Parikh RM. India; The Diabetes Capital of the World: Now heading Towards Hypertension. J Assoc Physicians India 2007;55:323-4.
11. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
12. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med 2007; June 5:[Epub ahead of print]
13. Krall RD. Cardiovascular safety of rosiglitazone. Published online May 30, 2007. The Lancet 2007. DOI:10.1016/S0140-6736(07)60824-1.
14. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJV. For the RECORD Study Group. Rosiglitazone Evaluated for Cardiovascular Outcomes - An Interim Analysis. N Engl J Med 2007; June 5:[Epub ahead of print]
15. Drazen JM, Morrissey S, Curfman GD. Rosiglitazone - Continued Uncertainty about safety. N Engl J Med 2007; June 5:[Epub ahead of print]
16. Nathan DM. Rosiglitazone and cardiotoxicity - weighing the evidence. N Engl J Med 2007; June 5:[Epub ahead of print]
17. Psaty BM, Furberg CD. The Record of rosiglitazone and the risk of myocardial infarction. N Engl J Med 2007; June 5:[Epub ahead of print].
18. Mohan V. Why are Indians more prone to diabetes? J Assoc Physicians India 2004; 52; 468-74.
19. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2001; 104:2855-64.
20. Chaturvedi N, Bilous R, Hardy R, Remuzzi G, Ruggenenti P, Viberti GC. Misleading meta-analysis: a need to look beyond the headlines. Diabet Med 2007;24:587-91.
21. Joshi SR. "Polypill-aspostatinoprilololazide folate"- coprescription for at the risk Asian Indian in chronic non communicable diseases. J Assoc Physicians India 2005; 53 : 175-8.